Fig. 2: Myristic acid inhibits immune responses against HSV-1 in vivo. | Nature Communications

Fig. 2: Myristic acid inhibits immune responses against HSV-1 in vivo.

From: Myristic acid as a checkpoint to regulate STING-dependent autophagy and interferon responses by promoting N-myristoylation

Fig. 2

a Quantitative polymerase chain reaction (qPCR) analysis of HSV-1 UL30 mRNA level in peritoneal macrophages (PMs) pretreated with solvent (mock) or myristic acid, and then infected with HSV-1, n = 3 samples examined over 3 independent experiments. b–g C57BL/6J mice were pretreated with myristic acid, and then infected with HSV-1 (2 × 107 p.f.u. per mouse) by intraperitoneal injection. Serum levels of IFN-β, IL-6, and TFN-α were analyzed by enzyme-linked immunosorbent assay (ELISA) (PBS group, n = 2; mock HSV-1 group, n = 6) (b). Immunohistochemistry (IHC) analysis of HSV-1 protein ICP5. Scale bar, 100 μm (c and d). qPCR analysis of HSV-1 UL30 mRNA level in lung, brain, and spleen (PBS group, n = 2; mock HSV-1 group, n = 4) (e). Haematoxylin and eosin staining of lung tissue sections. Scale bar, 100 μm (f), data are shown as typical photographs and are representative of biological samples (PBS group, n = 2; mock HSV-1 group, n = 4). Kaplan–Meier method was used to evaluate survival curves (n = 14 per group) (g). Statistical significance was determined by unpaired two-sided multiple Student’s t-tests in (a), (b), (d), and (e) or the log-rank Mantel–Cox test in (g). Data are shown as mean ± standard deviation (SD). *P < 0.05, ***P < 0.001. Source data is provided in the Source data file.

Back to article page